本文選題：上皮性卵巢癌 + 人附睪分泌蛋白��； 參考：《中國實用婦科與產(chǎn)科雜志》2015年07期

【摘要】：目的探討血清中腫瘤標志物人附睪分泌蛋白4(HE4)、糖鏈多肽抗原125(CA125)和卵巢惡性腫瘤風險預測模型(ROMA)預測和診斷上皮性卵巢癌的臨床價值。方法回顧性分析于2012年1月至2014年4月天津市中心婦產(chǎn)科醫(yī)院因盆腔腫物就診的225例病人,其中卵巢上皮癌113例,卵巢良性腫瘤112例,因體檢來院的健康婦女33例。采用電化學發(fā)光法測定受試者術前血清HE4和CA125濃度,用卵巢風險評估模型計算ROMA指數(shù)。結果卵巢癌組CA125、HE4及ROMA值高于卵巢良性腫瘤組和健康對照組,差異均有統(tǒng)計學意義(P0.05)。卵巢良性腫瘤組CA125、HE4及ROMA值與健康對照組比較,差異無統(tǒng)計學意義(P0.05)。HE4、CA125、ROMA值診斷卵巢惡性腫瘤的敏感度分別為52.21%、85.84%、86.73%,特異度分別為100%、88.39%、83.93%,三者相比較,ROMA值的敏感度最好,HE4特異度最好。ROMA值絕經(jīng)前后敏感度分別為85.71%和69.77%,特異度分別為86.90%和75%。結論HE4作為一種新型腫瘤標志物,其在卵巢上皮性癌中具有重要的診斷價值,而ROMA值預測患卵巢癌風險的敏感度較CA125、HE4二者單項高,有助于幫助臨床醫(yī)生評估患卵巢上皮性癌的風險性。
[Abstract]:Objective to evaluate the clinical value of serum tumor markers human epididymal secreting protein 4He-4H, carbohydrate polypeptide antigen 125 CA125) and ovarian malignant tumor risk prediction model (ROMA) in the prediction and diagnosis of epithelial ovarian cancer (EOC). Methods from January 2012 to April 2014, 225 patients with pelvic masses in Tianjin Center Obstetrics and Gynecology Hospital were retrospectively analyzed, including 113 cases of epithelial ovarian carcinoma, 112 cases of benign ovarian tumor, and 33 cases of healthy women who came to the hospital because of physical examination. Serum HE4 and CA125 concentrations were measured by electrochemiluminescence (ECL) and ROMA index was calculated by ovarian risk assessment model. Results the values of CA125 HE4 and ROMA in ovarian cancer group were higher than those in benign ovarian tumor group and healthy control group (P 0.05). The values of CA125, HE4 and ROMA in benign ovarian tumor group were compared with those in healthy control group. There was no significant difference in the sensitivity of P0.05, HE4, CA125U and ROMA in the diagnosis of ovarian malignant tumors. The sensitivity was 52.21 and 85.84, and the specificity was 86.73 and the specificity was 100 88.399.93, respectively. The best sensitivity of HE4 was 85.71% and 69.77% before and after menopause, and the specificity was 86.90% and 75m respectively. Conclusion as a new tumor marker, HE4 has an important diagnostic value in epithelial ovarian carcinoma. The sensitivity of ROMA in predicting the risk of ovarian cancer is higher than that of CA125 and HE4. Helps clinicians assess the risk of epithelial ovarian cancer.
【作者單位】： 天津市中心婦產(chǎn)科醫(yī)院;天津醫(yī)科大學;
【分類號】：R737.31

【參考文獻】

相關期刊論文 前7條

1 陳亮香;王冬蓮;李雪英;廖湘玲;;ROMA與RMI預測卵巢癌風險指數(shù)的比較研究[J];湖南中醫(yī)藥大學學報;2013年06期

2 聶代靜;陳曉品;;CA125、HE4聯(lián)合檢測及ROMA模型在卵巢癌診斷及預后方面的研究進展[J];臨床腫瘤學雜志;2013年06期

3 李青;宋曉玲;楊毓琴;;ROMA在卵巢上皮性癌早期診斷中的研究進展[J];現(xiàn)代生物醫(yī)學進展;2011年24期

4 陳燕;林鶯鶯;鄭瑜宏;胡敏華;陳巖松;;血清HE4、CA125和ROMA指數(shù)評估卵巢癌風險性的初步評價[J];中國免疫學雜志;2013年02期

5 王s，

本文編號：1984272